{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T21:11:55Z","timestamp":1790370715477,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002839","name":"Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002839","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017268","name":"Berlin Institute of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100017268","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ctro.science","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical and Translational Radiation Oncology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ctro.2025.101092","type":"journal-article","created":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T00:40:15Z","timestamp":1764981615000},"page":"101092","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Prospective controlled study comparing patient-reported outcomes after daily online adaptive radiotherapy or conventional IGRT in patients with prostate cancer"],"prefix":"10.1016","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3798-1546","authenticated-orcid":false,"given":"Goda","family":"Kalinauskaite","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1703-0105","authenticated-orcid":false,"given":"Luise A.","family":"K\u00fcnzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Rubarth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thao","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"Dannehl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celina","family":"H\u00f6hne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Beck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7944-3757","authenticated-orcid":false,"given":"Julia","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Zips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolin","family":"Senger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctro.2025.101092_b0005","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1001\/jamaoncol.2022.6558","article-title":"Magnetic resonance imaging\u2013guided vs computed tomography\u2013guided stereotactic body radiotherapy for prostate cancer: the MIRAGE randomized clinical trial","volume":"9","author":"Kishan","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ctro.2025.101092_b0010","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/S1470-2045(24)00720-4","article-title":"The interplay between acute and late toxicity among patients receiving prostate radiotherapy: an individual patient data meta-analysis of six randomised trials","volume":"26","author":"Nikitas","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctro.2025.101092_b0015","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1200\/JCO.20.02873","article-title":"Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: results from the FLAME randomized phase III trial","volume":"39","author":"Kerkmeijer","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctro.2025.101092_b0020","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","article-title":"Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial","volume":"17","author":"Dearnaley","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctro.2025.101092_b0025","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.radonc.2018.12.011","article-title":"MRI commissioning of 1.5T MR-linac systems \u2013 a multi-institutional study","volume":"132","author":"Tijssen","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctro.2025.101092_b0030","first-page":"77","article-title":"Making on-line adaptive radiotherapy possible using artificial intelligence and machine learning for efficient daily re-planning","volume":"8","author":"Archambault","year":"2020","journal-title":"MPI"},{"key":"10.1016\/j.ctro.2025.101092_b0035","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1308406","article-title":"Dosimetric benefit of online treatment plan adaptation in stereotactic ultrahypofractionated MR-guided radiotherapy for localized prostate cancer","volume":"14","author":"Fink","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctro.2025.101092_b0040","article-title":"Stereotactic ultrahypofractionated MR-guided radiotherapy for localized prostate cancer - acute toxicity and patient-reported outcomes in the prospective, multicenter SMILE phase II trial","volume":"46","author":"Fink","year":"2024","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.ctro.2025.101092_b0045","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/acm2.13399","article-title":"Prospects for daily online adaptive radiotherapy via ethos for prostate cancer patients without nodal involvement using unedited CBCT auto-segmentation","volume":"22","author":"Moazzezi","year":"2021","journal-title":"J Appl Clin Med Phys"},{"key":"10.1016\/j.ctro.2025.101092_b0050","doi-asserted-by":"crossref","DOI":"10.1002\/acm2.13479","article-title":"Varian ethos online adaptive radiotherapy for prostate cancer: early results of contouring accuracy, treatment plan quality, and treatment time","volume":"23","author":"Byrne","year":"2022","journal-title":"J Appl Clin Med Phys"},{"key":"10.1016\/j.ctro.2025.101092_b0055","article-title":"CT-based online adaptive radiotherapy improves target coverage and organ at risk (OAR) avoidance in stereotactic body radiation therapy (SBRT) for prostate cancer","volume":"44","author":"Waters","year":"2024","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.ctro.2025.101092_b0060","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.radonc.2021.12.013","article-title":"Online adaptive radiotherapy potentially reduces toxicity for high-risk prostate cancer treatment","volume":"167","author":"Christiansen","year":"2022","journal-title":"Radiother Oncol: J Eur Soc Ther Radiol Oncol"},{"key":"10.1016\/j.ctro.2025.101092_b0065","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1379596","article-title":"Magnetic resonance image-guided adaptive radiotherapy enables safe CTV-to-PTV margin reduction in prostate cancer: a cine MRI motion study","volume":"14","author":"Westley","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctro.2025.101092_b0070","article-title":"Intrafraction motion and margin assessment for ethos online adaptive radiotherapy treatments of the prostate and seminal vesicles","volume":"9","author":"Byrne","year":"2024","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.ctro.2025.101092_b0075","article-title":"MRI-guided radiotherapy in twenty fractions for localised prostate cancer; results from the MOMENTUM study","volume":"46","author":"Sritharan","year":"2024","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.ctro.2025.101092_b0080","unstructured":"Schaeffer EM, Srinivas N, Ahmed B, An Y, Bitting R, Chapin B, et al. NCCN clinical practice guidelines in oncology, prostate cancer. 2025."},{"key":"10.1016\/j.ctro.2025.101092_b0085","article-title":"Optimizing workflow for cone beam computed tomography-based online adaptive radiation therapy toward reduced physician involvement","volume":"10","author":"Kalinauskaite","year":"2025","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.ctro.2025.101092_b0090","first-page":"31","article-title":"Development and results of a patient-reported treatment experience questionnaire on a 1.5T MR-linac. Clin Transl","volume":"30","author":"Barnes","year":"2021","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ctro.2025.101092_b0095","unstructured":"Sand M, Wei J, Litwi M. Scoring Instructions for the E xpanded Prostate cancer Index Composite (EPIC) [Internet]. [cited 2025 Nov 5]. Available from: https:\/\/www.dropbox.com\/scl\/fi\/0qrvnygicl0bzg1k3zov9\/Urology-EPICScoringUtilitiesScoringDocumentation.pdf?rlkey=4vwvcze42e6vxlpe7loc38em4&e=1&st=do2s9gp5&dl=0."},{"key":"10.1016\/j.ctro.2025.101092_b0100","unstructured":"EORTC QLQ-C30 Scoring Manual [Internet]. EORTC; 2001 [cited 2025 Feb 27]. Available from: https:\/\/www.eortc.org\/app\/uploads\/sites\/2\/2018\/02\/SCmanual.pdf."},{"key":"10.1016\/j.ctro.2025.101092_b0105","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.urology.2014.08.044","article-title":"Minimally important difference for the expanded prostate cancer index composite short form","volume":"85","author":"Skolarus","year":"2015","journal-title":"Urology"},{"key":"10.1016\/j.ctro.2025.101092_b0110","first-page":"40","article-title":"Patient reported toxicity and quality of life after hypofractionated high-dose intensity-modulated radiotherapy for intermediate- and high risk prostate cancer","volume":"29","author":"Houben","year":"2021","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.ctro.2025.101092_b0115","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.euo.2021.07.005","article-title":"Impact of hypofractionated radiotherapy on patient-reported outcomes in prostate cancer: results up to 5 yr in the CHHiP trial (CRUK\/06\/016)","volume":"4","author":"Staffurth","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.ctro.2025.101092_b0130","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1016\/j.ijrobp.2025.06.1104","article-title":"Daily online adaptive recontouring for prostate cancer using 1.5 tesla magnetic resonance image guidance (MRgRT) improves patient reported urinary symptoms, a prospective, international, observational cohort study (NCT04075305)","volume":"123","author":"Hall","year":"2025","journal-title":"Int J Radiat Oncol*Biol*Phys"},{"key":"10.1016\/j.ctro.2025.101092_b0135","unstructured":"Chavarriaga J. ASTRO 2025: Daily Online Adaptive Recontouring for Prostate Cancer Using 1.5 Tesla Magnetic Resonance Image Guidance (MRgRT) Improves Patient Reported Urinary Symptoms, A Prospective, International, Observational Cohort Study (NCT04075305). UroToday [Internet]. 2025 Sept 30 [cited 2025 Oct 20]; Available from: https:\/\/www.urotoday.com\/conference-highlights\/astro-2025\/astro-2025-prostate-cancer\/163503-astro-2025-daily-online-adaptive-recontouring-for-prostate-cancer-using-1-5-tesla-magnetic-resonance-image-guidance-mrgrt-improves-patient-reported-urinary-symptoms-a-prospective-international-observational-cohort-study-nct04075305.html."},{"key":"10.1016\/j.ctro.2025.101092_b0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2025.111207","article-title":"CT online adaptive radiotherapy is associated with dosimetric and acute toxicity improvements in prostate cancer treatment","volume":"213","author":"Zhu","year":"2025","journal-title":"Radiother Oncol"}],"container-title":["Clinical and Translational Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630825001843?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630825001843?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T12:21:36Z","timestamp":1770034896000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405630825001843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":26,"alternative-id":["S2405630825001843"],"URL":"https:\/\/doi.org\/10.1016\/j.ctro.2025.101092","relation":{},"ISSN":["2405-6308"],"issn-type":[{"value":"2405-6308","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prospective controlled study comparing patient-reported outcomes after daily online adaptive radiotherapy or conventional IGRT in patients with prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical and Translational Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctro.2025.101092","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology.","name":"copyright","label":"Copyright"}],"article-number":"101092"}}